12 analysts have expressed a variety of opinions on Regeneron Pharmaceuticals (NASDAQ:REGN) over the past quarter, offering a diverse set of opinions from bullish to bearish.

The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.

Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $1068.58, along with a high estimate of $1184.00 and a low estimate of $850.00. Observing a 3.16% increase, the current average has risen from the previous average price target of $1035.86.

Analyzing Analyst Ratings: A Detailed Breakdown

An in...